Disposition Kinetics and Metabolism of Nicotine and Cotinine in African American Smokers: Impact of CYP2A6 Genetic Variation and Enzymatic Activity

Overview

Journal Pharmacogenet Genomics

Specialties Genetics
Pharmacology

Date 2016 Apr 2

PMID 27035242

Citations 27

Authors

Neal L Benowitz

Gideon St Helen

Delia A Dempsey

Peyton Jacob 3rd

Rachel F Tyndale

Affiliations

Soon will be listed here.

Abstract

Objective: The rate of nicotine metabolism, determined primarily by CYP2A6 activity, influences tobacco dependence and smoking-induced disease risk. The prevalence of CYP2A6 gene variants differs by race, with greater numbers in African Americans compared with Caucasians. We studied nicotine disposition kinetics and metabolism by the CYP2A6 genotype and enzymatic activity, as measured by the nicotine metabolite ratio (NMR), in African American smokers.

Methods: Participants were administered intravenous infusions of deuterium-labeled nicotine and cotinine. Plasma and urine concentrations of nicotine and metabolites were measured and pharmacokinetic parameters were estimated.

Results: Pharmacokinetic parameters and urine metabolite excretion data were analyzed by CYP2A6 genotype and by NMR. A number of gene variants were associated with markedly reduced nicotine and cotinine clearances. NMR was strongly correlated with nicotine (r=0.72) and cotinine (r=0.80) clearances. Participants with higher NMR excreted significantly greater nicotine C-oxidation and lower non-C-oxidation products compared with lower NMR participants.

Conclusion: CYP2A6 genotype, NMR, and nicotine pharmacokinetic data may inform studies of individual differences in smoking behavior and biomarkers of nicotine exposure.

Citing Articles

Tobacco Biomarkers by Latino Heritage and Race, US, 2007 to 2014 National Health and Nutrition Examination Survey.

Duong C, Rodriquez E, Hinerman A, Hooshmand S, Claudel S, Benowitz N Cancer Epidemiol Biomarkers Prev. 2024; 33(12):1586-1597.

PMID: 39348098 PMC: 11611627. DOI: 10.1158/1055-9965.EPI-24-0744.

Fine-mapping the CYP2A6 regional association with nicotine metabolism among African American smokers.

Pouget J, Giratallah H, Langlois A, El-Boraie A, Lerman C, Knight J Mol Psychiatry. 2024; 30(3):943-953.

PMID: 39217253 DOI: 10.1038/s41380-024-02703-5.

Association of Urinary Biomarkers of Tobacco Exposure with Lung Cancer Risk in African American and White Cigarette Smokers in the Southern Community Cohort Study.

Murphy S, Guillermo C, Thomson N, Carmella S, Wittmann M, Aldrich M Cancer Epidemiol Biomarkers Prev. 2024; 33(8):1073-1082.

PMID: 38780906 PMC: 11299762. DOI: 10.1158/1055-9965.EPI-23-1362.

Simultaneous Measurement and Distribution Analysis of Urinary Nicotine, Cotinine, Trans-3'-Hydroxycotinine, Nornicotine, Anabasine, and Total Nicotine Equivalents in a Large Korean Population.

Lee H, Chun M, Lee S Molecules. 2023; 28(23).

PMID: 38067415 PMC: 10708046. DOI: 10.3390/molecules28237685.

Nicotine Metabolite Ratio Decreases After Switching Off Efavirenz-Based Therapy in People With HIV Who Smoke.

Medaglio D, Bilker W, Han X, Merlin J, Plankey M, Martin J Clin Pharmacol Ther. 2023; 115(1):80-85.

PMID: 37787039 PMC: 10752215. DOI: 10.1002/cpt.3068.

References

Patterson F, Schnoll R, Wileyto E, Pinto A, Epstein L, Shields P . Toward personalized therapy for smoking cessation: a randomized placebo-controlled trial of bupropion. Clin Pharmacol Ther. 2008; 84(3):320-5. DOI: 10.1038/clpt.2008.57. View

Jacob 3rd P, Yu L, Wilson M, Benowitz N . Selected ion monitoring method for determination of nicotine, cotinine and deuterium-labeled analogs: absence of an isotope effect in the clearance of (S)-nicotine-3',3'-d2 in humans. Biol Mass Spectrom. 1991; 20(5):247-52. DOI: 10.1002/bms.1200200503. View

Levi M, Dempsey D, Benowitz N, Sheiner L . Prediction methods for nicotine clearance using cotinine and 3-hydroxy-cotinine spot saliva samples II. Model application. J Pharmacokinet Pharmacodyn. 2007; 34(1):23-34. DOI: 10.1007/s10928-006-9026-0. View

Dempsey D, Tutka P, Jacob 3rd P, Allen F, Schoedel K, Tyndale R . Nicotine metabolite ratio as an index of cytochrome P450 2A6 metabolic activity. Clin Pharmacol Ther. 2004; 76(1):64-72. DOI: 10.1016/j.clpt.2004.02.011. View

McDonagh E, Wassenaar C, David S, Tyndale R, Altman R, Whirl-Carrillo M . PharmGKB summary: very important pharmacogene information for cytochrome P-450, family 2, subfamily A, polypeptide 6. Pharmacogenet Genomics. 2012; 22(9):695-708. PMC: 3413746. DOI: 10.1097/FPC.0b013e3283540217. View

Benowitz N, Swan G, Jacob 3rd P, Lessov-Schlaggar C, Tyndale R . CYP2A6 genotype and the metabolism and disposition kinetics of nicotine. Clin Pharmacol Ther. 2006; 80(5):457-67. DOI: 10.1016/j.clpt.2006.08.011. View

Mwenifumbo J, Tyndale R . Genetic variability in CYP2A6 and the pharmacokinetics of nicotine. Pharmacogenomics. 2007; 8(10):1385-402. DOI: 10.2217/14622416.8.10.1385. View

Piliguian M, Zhu A, Zhou Q, Benowitz N, Ahluwalia J, Cox L . Novel CYP2A6 variants identified in African Americans are associated with slow nicotine metabolism in vitro and in vivo. Pharmacogenet Genomics. 2013; 24(2):118-28. PMC: 3931261. DOI: 10.1097/FPC.0000000000000026. View

Malaiyandi V, Sellers E, Tyndale R . Implications of CYP2A6 genetic variation for smoking behaviors and nicotine dependence. Clin Pharmacol Ther. 2005; 77(3):145-58. DOI: 10.1016/j.clpt.2004.10.011. View

10.

Hukkanen J, Jacob 3rd P, Benowitz N . Metabolism and disposition kinetics of nicotine. Pharmacol Rev. 2005; 57(1):79-115. DOI: 10.1124/pr.57.1.3. View

11.

Siahpush M, Singh G, Jones P, Timsina L . Racial/ethnic and socioeconomic variations in duration of smoking: results from 2003, 2006 and 2007 Tobacco Use Supplement of the Current Population Survey. J Public Health (Oxf). 2009; 32(2):210-8. DOI: 10.1093/pubmed/fdp104. View

12.

Zhu A, Renner C, Hatsukami D, Swan G, Lerman C, Benowitz N . The ability of plasma cotinine to predict nicotine and carcinogen exposure is altered by differences in CYP2A6: the influence of genetics, race, and sex. Cancer Epidemiol Biomarkers Prev. 2013; 22(4):708-18. PMC: 3617060. DOI: 10.1158/1055-9965.EPI-12-1234-T. View

13.

Fukami T, Nakajima M, Yoshida R, Tsuchiya Y, Fujiki Y, Katoh M . A novel polymorphism of human CYP2A6 gene CYP2A6*17 has an amino acid substitution (V365M) that decreases enzymatic activity in vitro and in vivo. Clin Pharmacol Ther. 2004; 76(6):519-27. DOI: 10.1016/j.clpt.2004.08.014. View

14.

Schnoll R, Patterson F, Wileyto E, Tyndale R, Benowitz N, Lerman C . Nicotine metabolic rate predicts successful smoking cessation with transdermal nicotine: a validation study. Pharmacol Biochem Behav. 2008; 92(1):6-11. PMC: 2657225. DOI: 10.1016/j.pbb.2008.10.016. View

15.

St Helen G, Novalen M, Heitjan D, Dempsey D, Jacob 3rd P, Aziziyeh A . Reproducibility of the nicotine metabolite ratio in cigarette smokers. Cancer Epidemiol Biomarkers Prev. 2012; 21(7):1105-14. PMC: 3392523. DOI: 10.1158/1055-9965.EPI-12-0236. View

16.

Lerman C, Tyndale R, Patterson F, Wileyto E, Shields P, Pinto A . Nicotine metabolite ratio predicts efficacy of transdermal nicotine for smoking cessation. Clin Pharmacol Ther. 2006; 79(6):600-8. DOI: 10.1016/j.clpt.2006.02.006. View

17.

Ho M, Mwenifumbo J, Zhao B, Gillam E, Tyndale R . A novel CYP2A6 allele, CYP2A6*23, impairs enzyme function in vitro and in vivo and decreases smoking in a population of Black-African descent. Pharmacogenet Genomics. 2008; 18(1):67-75. PMC: 2910083. DOI: 10.1097/FPC.0b013e3282f3606e. View

18.

Lerman C, Schnoll R, Hawk Jr L, Cinciripini P, George T, Wileyto E . Use of the nicotine metabolite ratio as a genetically informed biomarker of response to nicotine patch or varenicline for smoking cessation: a randomised, double-blind placebo-controlled trial. Lancet Respir Med. 2015; 3(2):131-138. PMC: 4480925. DOI: 10.1016/S2213-2600(14)70294-2. View

19.

Wassenaar C, Conti D, Das S, Chen P, Cook E, Ratain M . UGT1A and UGT2B genetic variation alters nicotine and nitrosamine glucuronidation in european and african american smokers. Cancer Epidemiol Biomarkers Prev. 2014; 24(1):94-104. PMC: 4294984. DOI: 10.1158/1055-9965.EPI-14-0804. View

20.

Benowitz N, Jacob 3rd P, Fong I, Gupta S . Nicotine metabolic profile in man: comparison of cigarette smoking and transdermal nicotine. J Pharmacol Exp Ther. 1994; 268(1):296-303. View